Literature DB >> 22864644

Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies.

Valentina Bova1, Roberto Miraglia, Luigi Maruzzelli, Giovanni Battista Vizzini, Angelo Luca.   

Abstract

PURPOSE: This study was designed to analyze the clinical results in patients suitable for liver transplantation with hepatocellular carcinoma (HCC) who exceeded Milan criteria, which underwent intra-arterial therapies (IAT), to determine predictive factors of successful downstaging.
METHODS: A total of 277 consecutive patients with cirrhosis and HCC were treated by IAT (transarterial oily chemoembolization, transarterial chemoembolization, transarterial embolization) in a single center. Eighty patients exceed the Milan criteria. Patients with infiltrative HCC, hypovascular HCC, and portal vein thrombosis were excluded, with a final study population of 48 patients. Tumor response to IAT was evaluated with CT and/or MRI according to modified RECIST criteria. Successful downstaging was defined as a reduction in the number and size of viable tumors to within the Milan criteria, and serum alpha-fetoprotein (AFP) <100 ng/mL, for at least 6 months.
RESULTS: Nineteen patients (39 %) had their tumors successfully downstaged; 29 patients (61 %) did not. Multivariate analysis showed that AFP level <100 ng/mL and 3-year calculated survival probability using the Metroticket calculator were the only independent predictors of successful downstaging (p < 0.023 and p < 0.049 respectively).
CONCLUSIONS: Biological characteristics of HCC as AFP levels <100 ng/mL and high 3-year calculated survival probability may predict a good response to downstage after IAT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22864644     DOI: 10.1007/s00270-012-0458-1

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  12 in total

1.  "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China.

Authors:  Jian-Yong Lei; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 2.  Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation.

Authors:  Wong Hoi She; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-14

Review 3.  Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.

Authors:  Arturo Soriano; Aranzazu Varona; Rajesh Gianchandani; Modesto Enrique Moneva; Javier Arranz; Antonio Gonzalez; Manuel Barrera
Journal:  World J Hepatol       Date:  2016-01-08

Review 4.  Downstaging for hepatocellular cancer: harm or benefit?

Authors:  Kathleen Bryce; Emmanuel A Tsochatzis
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-12

Review 5.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 6.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

7.  Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Authors:  Christine C Hsu; Abhishek Goyal; Alina Iuga; Saravanan Krishnamoorthy; Valerie Lee; Elizabeth C Verna; Shuang Wang; Fei-Na Chen; Rosa Rodriguez; Jean Emond; Paul Berk; Jay Lefkowitch; Lorna Dove; Robert S Brown; Abby B Siegel
Journal:  Clin Transl Gastroenterol       Date:  2015-02-05       Impact factor: 4.488

8.  Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis.

Authors:  Astrid Bauschke; Annelore Altendorf-Hofmann; Michael Ardelt; Herman Kissler; Hans-Michael Tautenhahn; Utz Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

Review 9.  Surgical management of hepatocellular carcinoma-Western versus Eastern attitude.

Authors:  Flavia Neri; Lorenzo Maroni; Matteo Ravaioli
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

Review 10.  Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation.

Authors:  Kohei Ogawa; Yasutsugu Takada
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.